ATE142255T1 - Verfahren zur herstellung eines aktivierten faktor vii-konzentrates mit einer hohen reinheit - Google Patents
Verfahren zur herstellung eines aktivierten faktor vii-konzentrates mit einer hohen reinheitInfo
- Publication number
- ATE142255T1 ATE142255T1 AT92403234T AT92403234T ATE142255T1 AT E142255 T1 ATE142255 T1 AT E142255T1 AT 92403234 T AT92403234 T AT 92403234T AT 92403234 T AT92403234 T AT 92403234T AT E142255 T1 ATE142255 T1 AT E142255T1
- Authority
- AT
- Austria
- Prior art keywords
- factor vii
- high purity
- activated factor
- producing
- free
- Prior art date
Links
- 108010054265 Factor VIIa Proteins 0.000 title abstract 4
- 239000012141 concentrate Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 4
- 108010023321 Factor VII Proteins 0.000 abstract 4
- 229940012413 factor vii Drugs 0.000 abstract 4
- 230000004913 activation Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 1
- 101000856746 Bos taurus Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 abstract 1
- 229930003448 Vitamin K Natural products 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940012414 factor viia Drugs 0.000 abstract 1
- 239000003456 ion exchange resin Substances 0.000 abstract 1
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
- 235000019168 vitamin K Nutrition 0.000 abstract 1
- 239000011712 vitamin K Substances 0.000 abstract 1
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract 1
- 229940046010 vitamin k Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9115601A FR2684999A1 (fr) | 1991-12-16 | 1991-12-16 | Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE142255T1 true ATE142255T1 (de) | 1996-09-15 |
Family
ID=9420096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92403234T ATE142255T1 (de) | 1991-12-16 | 1992-12-01 | Verfahren zur herstellung eines aktivierten faktor vii-konzentrates mit einer hohen reinheit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5344918A (OSRAM) |
| EP (1) | EP0547932B1 (OSRAM) |
| JP (1) | JP2533050B2 (OSRAM) |
| AT (1) | ATE142255T1 (OSRAM) |
| DE (2) | DE547932T1 (OSRAM) |
| DK (1) | DK0547932T3 (OSRAM) |
| ES (1) | ES2056782T3 (OSRAM) |
| FR (1) | FR2684999A1 (OSRAM) |
| GR (2) | GR930300094T1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5664362A (en) * | 1993-09-03 | 1997-09-09 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Fishing lure which releases the involuntary biting reflex of largemouth bass and other fishes within the family centrachidae |
| DE19538716A1 (de) * | 1995-10-18 | 1997-04-24 | Behringwerke Ag | Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa) |
| DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| DE19538715A1 (de) | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| AU781717B2 (en) * | 1998-04-24 | 2005-06-09 | Csl Behring Gmbh | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography |
| AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
| US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US7049110B2 (en) | 1998-07-21 | 2006-05-23 | Gambro, Inc. | Inactivation of West Nile virus and malaria using photosensitizers |
| US7498156B2 (en) | 1998-07-21 | 2009-03-03 | Caridianbct Biotechnologies, Llc | Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| US6444788B1 (en) * | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
| US7094378B1 (en) | 2000-06-15 | 2006-08-22 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US7220747B2 (en) | 1999-07-20 | 2007-05-22 | Gambro, Inc. | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
| DE19937218A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
| US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
| US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
| US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
| TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
| US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| ES2325653T3 (es) | 2001-12-21 | 2009-09-11 | Novo Nordisk Health Care Ag | Composicion liquida de polipeptidos del factor vii. |
| DK2283856T3 (da) | 2002-06-21 | 2017-11-20 | Novo Nordisk Healthcare Ag | Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider |
| RU2364626C2 (ru) | 2003-03-18 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x |
| US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| CA2525224A1 (en) | 2003-05-23 | 2004-12-02 | Michael Bech Jensen | Protein stabilization in solution |
| ATE547114T1 (de) | 2003-06-25 | 2012-03-15 | Novo Nordisk Healthcare Ag | Flüssige zusammensetzungen von factor vii polypeptiden |
| EP1656158B1 (en) | 2003-08-14 | 2016-03-09 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| MXPA06001814A (es) * | 2003-08-21 | 2006-05-04 | Novo Nordisk As | Separacion de polipeptidos que comprenden un aminoacido racemizado. |
| CN1917861B (zh) | 2003-12-19 | 2012-03-21 | 诺和诺德医疗保健公司 | 因子vii多肽的稳定化固体组合物 |
| CN102718859A (zh) * | 2004-09-29 | 2012-10-10 | 诺和诺德医疗保健公司 | 通过分级洗脱从阴离子交换材料中纯化批量凝血因子vii多肽 |
| ES2257225B1 (es) * | 2006-02-17 | 2007-03-16 | Grifols, S.A | Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion. |
| FR2901707B1 (fr) * | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| FR2917414B1 (fr) * | 2007-06-15 | 2012-07-13 | Lab Francais Du Fractionnement | Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci |
| FR2942231B1 (fr) | 2009-02-19 | 2015-03-20 | Lfb Biotechnologies | Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations |
| EP2652491B1 (en) | 2010-12-15 | 2017-11-29 | Baxalta GmbH | Eluate collection using conductivity gradient |
| EP2687595B1 (en) | 2012-07-19 | 2018-05-30 | Laboratoire Français du Fractionnement et des Biotechnologies | Method for purifying transgenic factor VII |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5314604B2 (OSRAM) * | 1972-12-20 | 1978-05-18 | ||
| JPS57206620A (en) * | 1981-06-12 | 1982-12-18 | Cutter Lab | Blood coagulation promoter and manufacture |
| US4540473A (en) * | 1983-11-22 | 1985-09-10 | International Business Machines Corporation | Copper plating bath having increased plating rate, and method |
| US4470969A (en) * | 1983-12-02 | 1984-09-11 | Miles Laboratories, Inc. | Process for producing a concentrate of coagulation factors VII and VIIa |
| US4473553A (en) * | 1983-12-02 | 1984-09-25 | Miles Laboratories, Inc. | Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa |
| FR2632524B1 (fr) * | 1988-06-09 | 1992-03-13 | Fondation Nale Transfusion San | Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament |
-
1991
- 1991-12-16 FR FR9115601A patent/FR2684999A1/fr active Granted
-
1992
- 1992-12-01 AT AT92403234T patent/ATE142255T1/de active
- 1992-12-01 DE DE92403234T patent/DE547932T1/de active Pending
- 1992-12-01 ES ES92403234T patent/ES2056782T3/es not_active Expired - Lifetime
- 1992-12-01 EP EP92403234A patent/EP0547932B1/fr not_active Expired - Lifetime
- 1992-12-01 DE DE69213421T patent/DE69213421T2/de not_active Expired - Lifetime
- 1992-12-01 DK DK92403234.5T patent/DK0547932T3/da active
- 1992-12-10 US US07/988,776 patent/US5344918A/en not_active Expired - Lifetime
- 1992-12-16 JP JP4354440A patent/JP2533050B2/ja not_active Expired - Fee Related
-
1993
- 1993-09-30 GR GR930300094T patent/GR930300094T1/el unknown
-
1996
- 1996-12-04 GR GR960403286T patent/GR3021875T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE547932T1 (de) | 1994-02-03 |
| FR2684999B1 (OSRAM) | 1995-05-05 |
| ES2056782T1 (es) | 1994-10-16 |
| EP0547932B1 (fr) | 1996-09-04 |
| DE69213421D1 (de) | 1996-10-10 |
| GR3021875T3 (en) | 1997-03-31 |
| US5344918A (en) | 1994-09-06 |
| DK0547932T3 (da) | 1997-02-10 |
| DE69213421T2 (de) | 1997-04-03 |
| EP0547932A1 (fr) | 1993-06-23 |
| GR930300094T1 (en) | 1993-09-30 |
| JP2533050B2 (ja) | 1996-09-11 |
| JPH05345799A (ja) | 1993-12-27 |
| FR2684999A1 (fr) | 1993-06-18 |
| ES2056782T3 (es) | 1997-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE142255T1 (de) | Verfahren zur herstellung eines aktivierten faktor vii-konzentrates mit einer hohen reinheit | |
| DE69011859D1 (de) | Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums. | |
| ATE124997T1 (de) | Enzymatische entfernung einer aminoterminalen proteinsequenz. | |
| DE58902737D1 (de) | Verfahren zur herstellung pharmazeutischer mischungen. | |
| EP0355572A3 (en) | Peptide derivatives, their production and use | |
| ATE44236T1 (de) | Verfahren zur herstellung eines hochgereinigten antihaemophilfaktor-konzentrats. | |
| SE8104482L (sv) | Forfarande for framstellning av ett faktor viii (ahf)-hogkoncentrat | |
| AT399818B (de) | Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation | |
| ATE119196T1 (de) | Verfahren zur herstellung einer an faktor-viia angereicherten fraktion und ihre verwendung als arzneimittel. | |
| DE69427955D1 (de) | Verfahren zur Herstellung von 2,2-Difluorketensilylacetalen und alpha,alpha-Difluor-beta -Silyloxy-1,3-Dioxolan-4-Propansäureestern | |
| ATE80309T1 (de) | Verfahren zur herstellung eines konzentrates von alpha-1-antitrypsin von menschlicher plasmafraktion und seine verwendung als arzneimittel. | |
| ATE116636T1 (de) | Verfahren zur herstellung von 2,6- dichlordiphenylaminessigsäurederivaten. | |
| DK0378432T3 (da) | Peptider, deres anvendelse til inhibering af modningen af T-lymfocytter og aktiviteten af makrofager samt fremgangsmåder til deres fremstilling | |
| ATE174756T1 (de) | Zyklische anti-tumorpromotor-verbindungen, zusammensetzungen und verfahren zur herstellung sowie ihre verwendung | |
| ATE164190T1 (de) | Verfahren zur herstellung von butantetracarboxylat | |
| ATE92056T1 (de) | Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern. | |
| DE68928634D1 (de) | Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität | |
| DE3882154D1 (de) | Verfahren zur herstellung des pres 1/s2/s-hepatitis-b-antigens aus hefe. | |
| ATE323760T1 (de) | Verfahren zur herstellung eines eine hyaluronidase enthaltenden präparats | |
| DE68917379D1 (de) | Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind. | |
| DK0685492T3 (da) | Fremgangsmåde til fremstilling af molekylært ensartede hyperpolymere hæmoglobiner | |
| DE69803769D1 (de) | Verfahren zur herstellung von 3,3-dimethylbutyraldehyd | |
| AU3330184A (en) | Immune interferon and method for its purification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |